Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A.
Panova EA, Kleymenov DA, Shcheblyakov DV, Bykonia EN, Mazunina EP, Dzharullaeva AS, Zolotar AN, Derkaev AA, Esmagambetov IB, Sorokin II, Usachev EV, Noskov AN, Ivanov IA, Zatsepin TS, Dmitriev SE, Gushchin VA, Naroditsky BS, Logunov DY, Gintsburg AL. Panova EA, et al. Among authors: esmagambetov ib. Front Immunol. 2023 Feb 14;14:1098302. doi: 10.3389/fimmu.2023.1098302. eCollection 2023. Front Immunol. 2023. PMID: 36865543 Free PMC article.
Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection.
Shcheblyakov D, Esmagambetov I, Simakin P, Kostina L, Kozlov A, Tsibezov V, Grebennikova T, Chifanov D, Rumyantseva I, Boyarskaya N, Sizikova T, Shagarova N, Andrus А, Shatohina I, Syromyatnikova S, Kovalchuk A, Pantyukhov V, Borisevich S, Zubkova O, Tukhvatulin A, Logunov D, Naroditsky B, Gintsburg A. Shcheblyakov D, et al. Antiviral Res. 2019 Dec;172:104617. doi: 10.1016/j.antiviral.2019.104617. Epub 2019 Oct 5. Antiviral Res. 2019. PMID: 31593751
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Logunov DY, et al. Among authors: esmagambetov ib. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Lancet. 2020. PMID: 32896291 Free PMC article. Clinical Trial.
Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome.
Dolzhikova IV, Grousova DM, Zubkova OV, Tukhvatulin AI, Kovyrshina AV, Lubenets NL, Ozharovskaia TA, Popova O, Esmagambetov IB, Shcheblyakov DV, Evgrafova IM, Nedorubov AA, Gordeichuk IV, Gulyaev SA, Botikov AG, Panina LV, Mishin DV, Loginova SY, Borisevich SV, Deryabin PG, Naroditsky BS, Logunov DY, Gintsburg AL. Dolzhikova IV, et al. Among authors: esmagambetov ib. Acta Naturae. 2020 Jul-Sep;12(3):114-123. doi: 10.32607/actanaturae.11042. Acta Naturae. 2020. PMID: 33173601 Free PMC article.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Logunov DY, et al. Among authors: esmagambetov ib. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545094 Free PMC article. Clinical Trial.
20 results